MP0726
/ Molecular Partners, Orano
- LARVOL DELTA
Home
Next
Prev
1 to 1
Of
1
Go to page
1
October 30, 2025
The second RDT program slated for clinical development is MP0726, targeting mesothelin (MSLN)…
(GlobeNewswire)
- "The Company presented preclinical data on MP0726 at the 2025 Annual Meeting of the Society of Nuclear Medicine and Molecular Imaging (SNMMI) in June. The Company is planning to progress several programs in 2026, including MP0726."
Preclinical • Solid Tumor
1 to 1
Of
1
Go to page
1